PBMs On Capitol Hill: Why Pharma Will Miss Them When They Are Gone
Drug pricing “middlemen” had their day in the hot seat during a Senate Finance Committee hearing on drug pricing. But even amid the finger-pointing between industry and PBMs over the high cost of drugs, the PBM execs offered some strong reminders of their real value to industry in fending off more overt price interventions by government.
You may also be interested in...
US Drug Pricing Reforms: ASCO Hears About Bargaining Chips And Baby Steps
Former long-time congressional health staffer Rodney Whitlock discusses the status of prescription drug pricing reform policies in the administration and congress at the American Society for Clinical Oncology annual meeting.
The Return Of The “Specialty” Drug Pricing Debate In The US
Pharma has been almost wholly successful in shifting the ground in the US drug pricing debate away from high-cost “specialty” products and towards the large gap between list and net prices, with the most intense focus on older medicines like insulin. What happens when the debate shifts back?
Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform
Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.